Why Edesa Biotech, Inc.’s (EDSA) Stock Is Up 6.09%
As of Monday, October 05, Edesa Biotech, Inc.’s EDSA share price has surged by 6.09%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Cynthia McLaughlin
Rosalio Madrigal
Michael Rose
| Share Statistics | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $25.5 | $202.9 | 12% |
|
| Shares Out (Mil) | 9.0 | 55.4 | 20% |
|
| Institutional Ownership | 71.5% | 92.9% | 43% |
|
| Float (Mil) | 8.8 | 40.7 | 18% |
|
| Beta | 1.08 | 1.04 | 64% |
|
| Avg Daily Volume (000s) | 8,939 | 566 | 95% |
|
| Price Change (52-week) |
9.3% | 41.0% | 59% |
|
| Growth | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (2.4%) | (10.3%) | 37% |
|
| EPS (5yr) | 24.5% | 15.8% | 75 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (0.7%) | (15.7%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($14) | ($44) | 26% |
|
| EPS (TTM) | ($1.732) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($34) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | ($1) | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $44 | $144 | 16% |
|
| Valuation | EDSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 47.25 | 1.97 | 99% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (102.5%) | (47.4%) | 5% |
|
| ROE | (531.3%) | (53.5%) | 1% |
|
| Liabilities to Assets | 30.7% | 29.7% | 22% |
|
| F-Score | 1 | 3 | 1% |
|
Edesa Biotech, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors